Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Pediatric Infectious Diseases, C450, Medical College of Wisconsin, PO Box 1997, Milwaukee, WI 53201-1997, USA.
BMC Infect Dis. 2024 Jul 3;24(1):663. doi: 10.1186/s12879-024-09321-0.
Severe COVID-19 is uncommon, restricted to 19% of the total population. In response to the first virus wave (alpha variant of SARS-CoV-2), we investigated whether a biomarker indicated severity of disease and, in particular, if variable expression of angiotensin converting enzyme 2 (ACE2) in blood might clarify this difference in risk and of post COVID -19 conditions (PCC).
The IRB-approved study compared patients hospitalized with severe COVID-19 to healthy controls. Severe infection was defined requiring oxygen or increased oxygen need from baseline at admission with positive COVID-19 PCR. A single blood sample was obtained from patients within a day of admission. ACE2 RNA expression in blood cells was measured by an RT-PCR assay. Plasma ACE1 and ACE2 enzyme activities were quantified by fluorescent peptides. Plasma TIMP-1, PIIINP and MMP-9 antigens were quantified by ELISA. Data were entered into REDCap and analyzed using STATA v 14 and GraphPad Prism v 10.
Forty-eight patients and 72 healthy controls were recruited during the pandemic. ACE2 RNA expression in peripheral blood mononuclear cells (PBMC) was rarely detected acutely during severe COVID-19 but common in controls (OR for undetected ACE2: 12.4 [95% CI: 2.62-76.1]). ACE2 RNA expression in PBMC did not determine plasma ACE1 and ACE2 activity, suggesting alternative cell-signaling pathways. Markers of fibrosis (TIMP-1 and PIIINP) and vasculopathy (MMP-9) were additionally elevated. ACE2 RNA expression during severe COVID-19 often responded within hours to convalescent plasma. Analogous to oncogenesis, we speculate that potent, persistent, cryptic processes following COVID-19 (the renin-angiotensin system (RAS), fibrosis and vasculopathy) initiate or promote post-COVID-19 conditions (PCC) in susceptible individuals.
This work elucidates biological and temporal plausibility for ACE2, TIMP1, PIIINP and MMP-9 in the pathogenesis of PCC. Intersection of these independent systems is uncommon and may in part explain the rarity of PCC.
严重的 COVID-19 并不常见,仅占总人口的 19%。为应对第一波病毒(SARS-CoV-2 的 alpha 变体),我们研究了是否有一种生物标志物可以指示疾病的严重程度,特别是血液中血管紧张素转换酶 2 (ACE2) 的可变表达是否可以阐明这种风险差异以及 COVID-19 后病症 (PCC)。
这项经 IRB 批准的研究将因严重 COVID-19 住院的患者与健康对照组进行了比较。严重感染的定义是指需要氧气或入院时与 COVID-19 PCR 阳性相比需要增加氧气的患者。患者在入院后一天内获得单一血液样本。通过 RT-PCR 测定法测量血细胞中的 ACE2 RNA 表达。通过荧光肽定量测定血浆 ACE1 和 ACE2 酶活性。通过 ELISA 定量测定血浆 TIMP-1、PIIINP 和 MMP-9 抗原。数据输入 REDCap 并使用 STATA v 14 和 GraphPad Prism v 10 进行分析。
在大流行期间,招募了 48 名患者和 72 名健康对照组。在严重的 COVID-19 期间,外周血单核细胞 (PBMC) 中的 ACE2 RNA 表达很少被急性检测到,但在对照组中很常见(未检测到 ACE2 的 OR:12.4 [95%CI:2.62-76.1])。PBMC 中的 ACE2 RNA 表达并不能确定血浆 ACE1 和 ACE2 活性,表明存在替代的细胞信号通路。纤维化标志物(TIMP-1 和 PIIINP)和血管病变标志物(MMP-9)也升高。严重 COVID-19 期间的 ACE2 RNA 表达通常在数小时内对恢复期血浆有反应。类似肿瘤发生,我们推测 COVID-19 后(肾素-血管紧张素系统 (RAS)、纤维化和血管病变)持续存在的隐匿性、强烈的隐匿性过程会在易感个体中引发或促进 COVID-19 后病症 (PCC)。
这项工作阐明了 ACE2、TIMP1、PIIINP 和 MMP-9 在 PCC 发病机制中的生物学和时间合理性。这些独立系统的交叉很少见,这可能部分解释了 PCC 的罕见性。